Breast cancer treatment may force cells to ‘sleep’ rather than killing them and cause patients to relapse, scientists believe.
Researchers at Imperial College London studied how cancer cells respond to the commonly used hormone therapy, such as Tamoxifen.
In the laboratory, they found that some cancer cells went into a dormant state – where they are inactive but still alive – instead of being wiped out.
This may explain why some patients’ cancer becomes resistant to treatment or why the killer disease returns years later.
The team said their discovery could pave the way for new drugs which keep the ‘sleeper cells’ from waking up.

Researchers at Imperial College London studied how cancer cells respond to the commonly used hormone therapy, such as Tamoxifen (pictured)

Breast cancer treatment may force cells to ‘sleep’ rather than killing them, causing patients to relapse, scientists believe. (Pictured: Cancer cells in the laboratory – dormant ‘sleeper’ cells are red and active cancer cells are green)
Dr Luca Magnani, from Imperial’s Department of Surgery and Cancer, was the lead author of the study.
He said: ‘For a long time scientists have debated whether hormone therapies – which are a very effective treatment and save millions of lives – work by killing breast cancer cells or whether the drugs flip them into a dormant “sleeper” state.
‘This is an important question as hormone treatments are used on the majority of breast cancers.
‘Our findings suggest the drugs may actually kill some cells and switch others into this sleeper state.
‘If we can unlock the secrets of these dormant cells, we may be able to find a way of preventing cancer coming back, either by holding the cells in permanent sleep mode, or be waking them up and killing them.’
Around 268,600 American women an 55,200 British women are diagnosed with invasive breast cancer every year, figures show.
Hormone therapies are used to treat a type of breast cancer called oestrogen-receptor positive. These make up over 70 per cent of all breast cancers.
Usually the patient has surgery to remove the tumour, followed by a course hormone therapy – usually either aromatase inhibitors or Tamoxifen – to target oestrogren receptors.
However, around 30 per cent of breast cancer patients taking hormone therapies see their cancer eventually return – sometimes as long as 20 years after treatment.
This returning cancer is usually metastatic, meaning it has spread around the body, and the tumours are resistant to drugs.
In the study, published in the journal Nature Communications, the team looked at around 50,000 human breast cancer single cells in the lab.
They found that treating the cells with hormone treatment exposed a small proportion of them as being in a dormant state.
The team say the ‘sleeper cells’ provide clues as to why some breast cancer cells become resistant to treatment, causing a patient’s drugs to stop working, and their cancer to return

Aromatase inhibitors (AIs), such as Letrozole, are the main hormone treatment used for post menopausal women with breast cancer
The ‘sleeper cells’ were more likely to spread around the body, co-author of the study Dr Sung Pil Hong said.
‘Our experiments suggest these sleeper cells are more likely to travel around the body. They could then “awaken” once in other organs of the body, and cause secondary cancers,’ he said.
‘However, we still don’t know how these cells switch themselves into sleep mode – and what would cause them to wake up. These are questions that need to be addressed with further research.’
Dr Iros Barozzi, co-author of the study, also from the Department of Surgery and Cancer said: ‘These sleeper cells seem to be an intermediate stage to the cells becoming resistant to the cancer drugs.
‘The findings also suggest the drugs actually trigger the cancer cells to enter this sleeper state.’
The team added that hormone therapies remain one of the most effective treatments against breast cancer.
The research opens avenues for finding ways of keeping the cancer cells dormant for longer, or awakening the cells so they can then be killed by the treatment.
Further research will explore whether taking hormone therapies for longer after initial cancer treatment could prevent cancer cells from waking up.
Dr Rachel Shaw from Cancer Research UK, said: ‘Although treatments for breast cancer are usually successful, cancer returns for some women, often bringing with it a poorer prognosis.
‘Figuring out why breast cancer sometimes comes back is essential to help us develop better treatments and prevent this from happening.
‘This study highlights a key route researchers can now explore to tackle ‘sleeping’ cancer cells that can wake up years after treatment, which could potentially save the lives of many more women with the disease.’
The findings from the study, funded by Cancer Research UK and the NIHR Imperial Biomedical Research Centre, are only in the early stages.
Previous work by the same team has found evidence that suggests cells can make their own ‘fuel’, allowing them to avoid being ‘starved’ by cancer treatment.